A phase II study of pemetrexed as second-line chemotherapy for the treatment of metastatic castrate-resistant prostate cancer (CRPC); Hoosier Oncology Group GU03-67.

Hahn, N M; Zon, R T; Yu, M; Ademuyiwa, F O; Jones, T; Dugan, W; Whalen, C; Shanmugam, R; Skaar, T; Sweeney, C J

Hahn, N M; Zon, R T; Yu, M; Ademuyiwa, F O; Jones, T; Dugan, W; Whalen, C; Shanmugam, R; Skaar, T; Sweeney, C J.

Affiliation

Hahn NM; Department of Medicine, Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN, USA.

Ann Oncol ; 20(12): 1971-6, 2009 Dec.

Article in En | MEDLINE | ID: mdl-19605506

Subject(s)

Antineoplastic Agents/therapeutic use; Glutamates/therapeutic use; Guanine/analogs & derivatives; Orchiectomy; Prostatic Neoplasms/drug therapy; Aged; Aged, 80 and over; Antineoplastic Agents/adverse effects; Glutamates/adverse effects; Guanine/adverse effects; Guanine/therapeutic use; Humans; Male; Membrane Transport Proteins/genetics; Middle Aged; Mutation; Neoplasm Metastasis; Pemetrexed; Pharmacogenetics; Polymorphism, Genetic; Prostatic Neoplasms/genetics; Prostatic Neoplasms/pathology; Prostatic Neoplasms/surgery; Survival Analysis

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / Orchiectomy / Glutamates / Guanine / Antineoplastic Agents Limits: Aged / Aged80 / Humans / Male / Middle aged Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2009 Type: Article Affiliation country: United States

Fulltext

XML

PubMed Links

Search on Google